3P BIOTECHNOLOGIES, INC.
Prospect, KY · Biotech · Private
Exosome-based delivery system for CRISPR/Cas9 genome editing using engineered milk exosomes with targeted ligand functionalization
3pbiotechnologies.com →- Grants
- $4.5M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 1 granted · 1 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Exosomal Drug Delivery | $1,719,680 | |
| Federal grant | Department of Health and Human Services · Phase II · Exosomal Drug Delivery | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Engineered Exosomes for Targeted Delivery of the CRISPR/Cas9 Genome-editor | $264,507 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeted Exosomal Delivery of siRNA Therapeutics for Neuroinflammatory Diseases | $506,451 | |
| Federal grant | Department of Health and Human Services · Phase I · Trans Spinal Delivery of a Targeted Nanoformulation of Curcuminoids to Treat AD | $499,964 | |
| Federal grant | Department of Health and Human Services · Phase I · Trans Spinal Delivery of a Targeted Nanoformulation of Curcuminoids to Treat AD | $6,500 | |
| Federal grant | Department of Health and Human Services · Phase I · Trans Spinal Delivery of Targeted Exosomal Formulation of Curcuminoids to Treat AD | $506,434 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2334 | NEMAMETRIX, INC | — | $9.4M |
| 2335 | TERAIMMUNE, INC. | — | $3.0M |
| 2336 | Decibel Therapeutics | — | $63M |
| 2337 | 3P BIOTECHNOLOGIES, INC. | — | — |
| 2338 | Mythic Therapeutics | — | $53M |
| 2339 | DEEPSEQAI LLC | — | — |
| 2340 | Tallac Therapeutics, Inc. | — | $21M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Isolation of Exosomes from Colostrum Powder and Exosomal Drug Formulations Using the Samegranted
- Isolation and Characterization of Exosomes from Colostrum Powder, and Exosomal Drug Formulationsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.